AstraZeneca to discontinue Epanova trial, expects $100 million writedown

AstraZeneca said on Monday it will discontinue a late-stage trial for Epanova to treat patients with mixed dyslipidaemia at high risk of cardiovascular disease and expects a $100 million writedown to hit its core profit in the fourth quarter.

from Reuters: Health News https://ift.tt/2Nnd9ma